LYL273 for Patients With Relapsed or Refractory mCRC

This study tests a new type of CAR-T cell therapy called GCC19CART — immune cells engineered to attack a protein (GCC) found on colorectal cancer cells — in patients with metastatic colorectal cancer. **You may be eligible if...** - You have metastatic colorectal cancer confirmed by biopsy - Your cancer expresses the GCC protein - You have received and failed standard chemotherapy regimens - You are 18 or older - You have adequate organ function **You may NOT be eligible if...** - You have an active autoimmune condition - You have active brain metastases - You have had a prior CAR-T cell therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.